Literature DB >> 8539337

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

D Charrier1, L Dangoumau, A J Puech, M Hamon, M H Thiébot.   

Abstract

The effects of cholecystokinin (CCK) receptor ligands were studied in the rat safety signal withdrawal conflict procedure, an operant paradigm sensitive to both anxiolytic and anxiogenic compounds. In this procedure, behavioural suppression of lever pressing for food was induced by the withdrawal of a conditioned signal for safety without the usual presentation of a conditioned signal for danger. The compounds tested were selective CCK-B antagonists [CI-988 (0.01-1 mg/kg SC), L-365,260 (0.004-2 mg/kg IP) and LY 262,691 (0.001-1 mg/kg SC)], CCK-B agonists [CCK-4 (0.01-1 mg/kg SC) and BC 264 (0.004-1 mg/kg IP)] and CCK-A antagonists [devazepide (0.001-1 mg/kg SC) and lorglumide (0.01-1 mg/kg SC)]. None of these drugs induced the expected behavioural effects, i.e. an anxiolytic-like release of the behavioural suppression with CCK-B and, possibly, CCK-A antagonists and/or a further reduction of lever pressing with CCK-B agonists, indicative of an anxiogenic-like potential. In contrast, the established anxiolytic lorazepam (0.06-0.25 mg/kg IP), as well as diazepam (2 mg/kg IP) and buspirone (0.25 mg/kg SC) used as positive control drugs, released the suppression of pressing for food during the period associated with the safety signal withdrawal, whereas picrotoxin (1 mg/kg IP), used as an anxiogenic control, further reduced responding during this conflict period. The present results contrast with a series of published data suggesting the involvement of CCK processes in anxiety-related behaviour in rodent models such as the elevated plus-maze or the light:dark two compartment test, and in panic disorders in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539337     DOI: 10.1007/bf02245599

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  Anxiolytic effects of CCK-B antagonists.

Authors:  B Costall; A M Domeney; J Hughes; M E Kelly; R J Naylor; G N Woodruff
Journal:  Neuropeptides       Date:  1991-07       Impact factor: 3.286

Review 2.  CCK in animal and human research on anxiety.

Authors:  J Harro; E Vasar; J Bradwejn
Journal:  Trends Pharmacol Sci       Date:  1993-06       Impact factor: 14.819

3.  Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

Authors:  D J Dooley; I Klamt
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.

Authors:  J Bradwejn; D Koszycki
Journal:  Am J Psychiatry       Date:  1994-02       Impact factor: 18.112

5.  The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

Authors:  M J Bickerdike; C A Marsden; C T Dourish; A Fletcher
Journal:  Eur J Pharmacol       Date:  1994-12-27       Impact factor: 4.432

6.  The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Authors:  J Bradwejn; D Koszycki; A Couëtoux du Tertre; H van Megen; J den Boer; H Westenberg
Journal:  Arch Gen Psychiatry       Date:  1994-06

7.  Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

Authors:  A Rex; T Barth; J P Voigt; A M Domeney; H Fink
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

8.  Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.

Authors:  E Vasar; A Lang; J Harro; M Bourin; J Bradwejn
Journal:  Neuropharmacology       Date:  1994-06       Impact factor: 5.250

9.  Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

Authors:  J L Abelson; R M Nesse
Journal:  Biol Psychiatry       Date:  1994-07-15       Impact factor: 13.382

10.  CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

Authors:  V Daugé; P Steimes; M Derrien; N Beau; B P Roques; J Féger
Journal:  Pharmacol Biochem Behav       Date:  1989-09       Impact factor: 3.533

View more
  2 in total

1.  New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454.

Authors:  Bruno Bellier; Dominique Crété; Marie-Emmanuelle Million; Françoise Beslot; André Bado; Christiane Garbay; Valérie Daugé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-08       Impact factor: 3.000

2.  Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

Authors:  Qian Chen; Akira Nakajima; Corbin Meacham; Ya-Ping Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.